OPX Biotechnologies and Evonik Industries today announced the two companies have entered into an agreement to jointly develop certain bio-based specialty chemicals. The joint-development agreement signed May 3rd 2013 calls for Opxbio to use its proprietary EDGE (Efficiency Directed Genome Engineering) technology to develop the bio-processes.
Building on the April 2025 announcement, Dow will take actions across its three operating segments to support European profitability, resulting in the closure of sites in Germany and the UK.
Compelling solutions through strategic partnerships
Ineos CEO Ineos calls on European politicians to save the chemical industry.
Novo Nordisk announced a global workforce reduction of approximately 9,000 positions to streamline operations and reinvest DKK 8 billion (€1 billion) in growth opportunities for diabetes and obesity treatments.
